Compare Pfizer Inc (PFE) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Teradyne, Inc. — how do they compare? Pfizer Inc trades at $27.86 (market cap $158.56B), while Teradyne, Inc. trades at $405.46 (market cap $62.34B). The key difference: Pfizer Inc is far larger — about 2.5× Teradyne, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.18%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Teradyne, Inc. for 37 Days on average.
| PFE | TER | |
|---|---|---|
Market Cap | $158.56B | $62.34B |
Volume | 44,138,282 | 3,368,404 |
Sector | Health | Technology |
52-Week High | $29.02 | $483.84 |
52-Week Low | $23.67 | $132.05 |
Typical Hold Time | 158 Days | 37 Days |
Enterprise Value | $210.06B | $62.08B |
Dividend Yield | 6.18% | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $28.00, up 1.87% on the day, with a bullish technical signal from moving averages. The company reported revenue of $62.58 billion in 2025 with a net income margin of 6.8%, and has beaten EPS estimates for the last three quarters. Recent news highlights Pfizer's focus on its obesity and oncology pipeline as key growth drivers in 2026.
The stock presents a value opportunity with a consensus price target of $29.17, but faces risks from patent expirations and projected earnings decline. Investor sentiment is mixed, with analysts largely neutral, emphasizing the stock's defensive cash flow and dividend yield amid ongoing business transformation.
Teradyne (TER) trades at $411.78, down 4.31% today but maintains strong technical momentum with bullish moving averages and support at $407. The company demonstrates robust fundamentals with three consecutive earnings beats, 25.77% net margins, and 36.66% ROE. Recent product launches including Magnum E2 and Iris 100 position TER to capitalize on AI-driven semiconductor testing demand. Revenue is projected to grow from $3.19B in 2025 to $4.5B in 2026 according to company guidance.
TER presents a compelling growth opportunity with dominant positioning in semiconductor testing equipment and strong AI tailwinds. However, elevated valuation multiples (P/E 54.77, P/S 14.11) require continued execution. Key risks include semiconductor cycle volatility and competitive pressure from KLAC and COHU. Analyst consensus remains bullish with $461.50 price target representing 12% upside from current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
